Title
Category
Credits
Event date
Cost
  • CME Activities
  • Critical Care
  • Emergency
  • Imaging
  • Neurointervention
  • Neurology
  • Stroke
  • Telemedicine
  • Thrombolysis
  • Thrombolytics
  • Participation
$0.00
Join TeleSpecialists TeleNeurologist Sam Saha, MD as he shares details about the latest clinical trials supporting imaging-guided thrombolysis and thrombectomy decision-making that have demonstrated net benefit in subsets of patients with unknown onset of symptoms, most commonly after waking up. With wider implementation of advanced imaging augmented by artificial intelligence software, there is an argument for pushing stroke treatment boundaries long established by clinical decision-making alone.
  • Alteplase
  • Best Practices
  • CME Activities
  • Emergency
  • Stroke
  • Telemedicine
  • Thrombolysis
  • Thrombolytics
  • Participation
$0.00
  • CME Activities
  • Critical Care
  • Emergency
  • Neurology
  • Nursing Continuing Education
  • Stroke
  • Tenecteplase
  • Thrombolytics
  • Nursing Education Hours
  • Participation
$0.00
Intravenous thrombolytics is the mainstay of acute therapy in ischemic stroke.  While alteplase has been FDA-approved for this indication since the 1990s, Tenecteplase has recently gained traction for usage in acute ischemic stroke treatment as well.  This lecture summarizes the existing evidence and practical considerations for use of Tenecteplase in stroke therapy.  
  • Alteplase
  • Best Practices
  • CME Activities
  • Critical Care
  • Emergency
  • Neurology
  • Nursing Continuing Education
  • Stroke
  • Tenecteplase
  • Thrombolytics
  • Nursing Contact Hours
04/28/2022
$0.00
Join TeleSpecialists Dr. Theresa Sevilis, board-certified vascular neurologist to review the American Heart Association Guidelines for the Early Management of Patients with Acute Ischemic Stroke.  Dr. Sevilis will discuss the indications, relative contraindications, and absolute contraindications for thrombolytics, provide cases for review, and discuss how to use the Guidelines in the decision making process.  She will highlight the most commonly asked questions surrounding thrombolytic administration and discuss the new utilization of tenecteplase in place of alteplase.